Phlegmasia cerulea dolens: therapeutic considerations

Area of Science:

• Vascular Surgery
• Hematology
• Critical Care Medicine

Background:

• Phlegmasia cerulea dolens (PCD) presents a significant therapeutic challenge due to its rarity and severity.
• Malignant conditions are frequently associated with PCD, impacting patient outcomes.
• Venous gangrene (VG) is a critical complication, significantly increasing mortality.

Purpose of the Study:

• To evaluate the effectiveness of different treatment modalities for Phlegmasia cerulea dolens.
• To identify optimal treatment strategies based on disease severity and presence of venous gangrene.
• To inform future therapeutic trial design for PCD.

Main Methods:

• Retrospective review of 16 PCD cases treated over 15 years.
• Analysis of treatment outcomes with intravenous heparin, venous thrombectomy, and thrombolytic therapy.
• Comparison with 38 cases from recent literature.

Main Results:

• Nongangrenous PCD responded well to systemic anticoagulation (heparin) in 53% of cases.
• Venous thrombectomy, alone or in combination, was successful in 50% of cases, including one with early VG.
• All five patient deaths occurred in those with venous gangrene, irrespective of treatment intensity.

Conclusions:

• Nongangrenous Phlegmasia cerulea dolens demonstrates a favorable response to systemic anticoagulation.
• Combination therapy with venous thrombectomy and heparin is recommended for severe ischemia, early venous gangrene, or refractory cases.
• Phlegmasia cerulea dolens with venous gangrene represents a lethal form with poor response to current therapies, necessitating aggressive future treatment strategies.